A Smarter Approach for Patients

Treating respiratory patients systemically can lead to unwanted effects in the body owing to a lack of specificity and the need for high doses. At Pulmocide, we aim to deliver novel respiratory treatments easily and directly to the lung to maximize efficacy and minimize adverse effects.

More
Novel inhaled respiratory medicine development pipeline.

We are developing novel, potent first-in-class anti-infective agents for delivery by inhaled administration for life-threatening lower respiratory infections.

more

Management Team

  • Dan Burgess
    More
  • Dr Lance Berman
    More
  • Dr Pete Strong
    More
  • Jennifer Giottonini Cayer
    More
  • Dr David Mantus
    More
  • Joe Suarez
    More

Investors